Lipid Efficacy of the Extended Release Niacin/Laropiprant Combination in Patients With Cardiovascular Disease
Status:
Terminated
Trial end date:
2013-01-01
Target enrollment:
Participant gender:
Summary
- Clinical studies with statins have shown that patients that suffered a cardiovascular
event have a high residual risk. Residual risk decreases with the attaining of
progressive lower LDL-C levels.
- In patients treated with statins, HDL-C level is an independent inverse predictor of
subsequent CV and coronary plaque progression, even when LDL-C levels are less than 70
mg/dL.
- Therefore the purpose on this study is to assess the lipid efficacy on lipid profile and
effects on HDL-C metabolism and function of the extended release niacin/laropiprant
combination added to usual therapy in very high risk patients with cardiovascular
disease and low HDL-C that did not achieve the optional very low LDL-C or non-HDL-C
goals